Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York. Show more
One World Trade Center, New York, NY, 10007, United States
Market Cap
1.841B
52 Wk Range
$4.70 - $19.67
Previous Close
$18.47
Open
$18.40
Volume
1,519,531
Day Range
$18.24 - $19.37
Enterprise Value
1.465B
Cash
411.6M
Avg Qtr Burn
-42.98M
Insider Ownership
1.42%
Institutional Own.
71.78%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MM120 (lysergide D-tartrate) Details Major depressive disorder | Phase 3 Data readout | |
MM120 (lysergide D-tartrate) Details Anxiety Disorders | Phase 3 Data readout | |
MM402 (R(-)-MDMA) Details Autism spectrum disorders | Phase 2a Initiation |